CFTR and cystic fibrosis: In a phase 1/2 clinical study, inhaled CFTR mRNA (MRT5005) was delivered via lipid NP to adults with CF, demonstrating general safety and tolerability, although some subjects experienced mild to moderate fever and hypersensitivity reactions [343].